Oral EA - Search Results

1

Iron parameters in patients with partial lipodystrophy and impact of exogenous leptin therapy.

Akinci EY, Boutros S, Ryan BJ, Sargin P, Akinci B, Neidert AH, Hench R, Horowitz JF, Oral EA. Akinci EY, et al. Among authors: oral ea. BMJ Open Diabetes Res Care. 2021 Aug;9(1):e002385. doi: 10.1136/bmjdrc-2021-002385. BMJ Open Diabetes Res Care. 2021. PMID: 34373262 Free PMC article. No abstract available.

2

Leptin replacement therapy modulates circulating lymphocyte subsets and cytokine responsiveness in severe lipodystrophy.

Oral EA, Javor ED, Ding L, Uzel G, Cochran EK, Young JR, DePaoli AM, Holland SM, Gorden P. Oral EA, et al. J Clin Endocrinol Metab. 2006 Feb;91(2):621-8. doi: 10.1210/jc.2005-1220. Epub 2005 Nov 29. J Clin Endocrinol Metab. 2006. PMID: 16317060 Clinical Trial.

3

Rationale for leptin-replacement therapy for severe lipodystrophy.

Oral EA, Chan JL. Oral EA, et al. Endocr Pract. 2010 Mar-Apr;16(2):324-33. doi: 10.4158/EP09155.RA. Endocr Pract. 2010. PMID: 20061299 Review.

4

Leptin for type 1 diabetes: coming onto stage to be (or not?).

Oral EA. Oral EA. Pediatr Diabetes. 2012 Feb;13(1):68-73. doi: 10.1111/j.1399-5448.2011.00797.x. Epub 2011 Sep 14. Pediatr Diabetes. 2012. PMID: 21917108 Review.

5

Alterations in lipid signaling underlie lipodystrophy secondary to AGPAT2 mutations.

Subauste AR, Das AK, Li X, Elliott BG, Evans C, El Azzouny M, Treutelaar M, Oral E, Leff T, Burant CF. Subauste AR, et al. Diabetes. 2012 Nov;61(11):2922-31. doi: 10.2337/db12-0004. Epub 2012 Aug 7. Diabetes. 2012. PMID: 22872237 Free PMC article.

6

A subcutaneous adipose tissue-liver signalling axis controls hepatic gluconeogenesis.

Reilly SM, Ahmadian M, Zamarron BF, Chang L, Uhm M, Poirier B, Peng X, Krause DM, Korytnaya E, Neidert A, Liddle C, Yu RT, Lumeng CN, Oral EA, Downes M, Evans RM, Saltiel AR. Reilly SM, et al. Among authors: oral ea. Nat Commun. 2015 Jan 12;6:6047. doi: 10.1038/ncomms7047. Nat Commun. 2015. PMID: 25581158 Free PMC article. Clinical Trial.

7

A Report of Three Cases With Acquired Generalized Lipodystrophy With Distinct Autoimmune Conditions Treated With Metreleptin.

Lebastchi J, Ajluni N, Neidert A, Oral EA. Lebastchi J, et al. Among authors: oral ea. J Clin Endocrinol Metab. 2015 Nov;100(11):3967-70. doi: 10.1210/jc.2015-2589. Epub 2015 Sep 21. J Clin Endocrinol Metab. 2015. PMID: 26390101 Free PMC article.

8

Immunogenicity associated with metreleptin treatment in patients with obesity or lipodystrophy.

Chan JL, Koda J, Heilig JS, Cochran EK, Gorden P, Oral EA, Brown RJ. Chan JL, et al. Among authors: oral ea. Clin Endocrinol (Oxf). 2016 Jul;85(1):137-49. doi: 10.1111/cen.12980. Epub 2016 Feb 2. Clin Endocrinol (Oxf). 2016. PMID: 26589105 Free PMC article. Clinical Trial.

9

Efficacy and Safety of Metreleptin in Patients with Partial Lipodystrophy: Lessons from an Expanded Access Program.

Ajluni N, Dar M, Xu J, Neidert AH, Oral EA. Ajluni N, et al. Among authors: oral ea. J Diabetes Metab. 2016 Mar;7(3):659. doi: 10.4172/2155-6156.1000659. Epub 2016 Mar 23. J Diabetes Metab. 2016. PMID: 27642538 Free PMC article.

10

Spectrum of disease associated with partial lipodystrophy: lessons from a trial cohort.

Ajluni N, Meral R, Neidert AH, Brady GF, Buras E, McKenna B, DiPaola F, Chenevert TL, Horowitz JF, Buggs-Saxton C, Rupani AR, Thomas PE, Tayeh MK, Innis JW, Omary MB, Conjeevaram H, Oral EA. Ajluni N, et al. Among authors: oral ea. Clin Endocrinol (Oxf). 2017 May;86(5):698-707. doi: 10.1111/cen.13311. Epub 2017 Mar 27. Clin Endocrinol (Oxf). 2017. PMID: 28199729 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

133 results

Search Page

Filters